Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

lupus

Research Partnership publishes 2016 Living with RA reports

Research Partnership has published new Living with rheumatoid arthritis (RA) EU and US market reports for 2016.

Research Partnership

- PMLiVE

GSK and J&J move closer to sirukumab filing for arthritis

On course for third quarter application in a bid to catch up with Sanofi’s sarilumab

- PMLiVE

Videum supports online campaign to reach ‘underserved’ RA patients

The project provides educational resources to the UK's South Asian communities

- PMLiVE

Positive trials bring Pfizer closer to new use for Xeljanz

Rheumatoid arthritis drug performs in two ulcerative colitis trials

Sanofi reception

Sanofi’s sarilumab beats Humira in head-to-head trial

Rheumatoid arthritis candidate was more effective than AbbVie's market-leader

Living with RA Report

Living with Rheumatoid Arthritis 2016 is a new syndicated report which offers low-cost, high-value quantitative insight into patient attitudes and behaviour.

Research Partnership

Gilead Sciences

Gilead wins US approval for second TAF-based HIV drug

FDA gives Odefsey the green light

- PMLiVE

Stem cell therapy promising for rheumatoid arthritis

Mesoblast’s phase II trial sees "impressive efficacy" in refractory patients

Gilead Sciences

Priority FDA review for new Gilead HCV combination therapy

Sovaldi/velpatasvir combination could be approved in the US by summer 2016

- PMLiVE

GSK plans sirukumab filing in rheumatoid arthritis next year

Says phase III trials showed 'no unexpected safety findings'

Gilead Sciences

Gilead steps into breach left by AbbVie as Galapagos’ partner

Deal worth $2bn to help rheumatoid arthritis drug filgotinib make it through to the market

Gilead Sciences

Gilead’s HIV drug Genvoya cleared in EU

First TAF-based regimen to be approved in the US and EU

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links